Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response

Arthritis and Rheumatism

Volumn 58, Issue 2, 2008, Pages 604-611

  Landau, Dan Avi ^a,b   Saadoun, David ^a,b   Halfon, Philippe ^c   Martinot Peignoux, Michelle ^d   Marcellin, Patrick ^d   Fois, Elena ^e   Cacoub, Patrice ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Laboratoire Alphabio   (France)

^d BEAUJON HOSPITAL   (France)

^e Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHLORAMBUCIL; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA; RIBAVIRIN; STEROID; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; CRYOPRECIPITATE; DISEASE ASSOCIATION; FEMALE; HEPATITIS C VIRUS; HUMAN; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PURPURA; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA TRANSCRIPTION; TREATMENT DURATION; TREATMENT OUTCOME; VASCULITIS; VIRUS INFECTION; VIRUS REPLICATION;

ADULT; AGED; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; VASCULITIS; VIRUS REPLICATION;

EID: 39749085148     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23305     Document Type: Article

References (37)

1. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term followup of 40 patients. Am J Med 1980;69:287-308.
2. D'Amico G, Colasanti G, Ferrario F, Sinico RA. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989;35:1004-14.
3. Frankel AH, Singer DR, Winearls CG, Evans DJ, Rees AJ, Pusey CD. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992;82:101-24.
4. Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, et al. Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317-26.
5. Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Long-term efficacy of interferon-α for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001;28:2466-73.
6. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α. J Rheumatol 2000;27:2172-8.
7. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54:3696-706.
8. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43:617-23.
9. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
10. Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, et al. Interferon-α in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993;81:1132-6.
11. Casato M, Agnello V, Pucillo LP, Knight GB, Lconi M, Del Vecchio S, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865-73.
12. Martinot-Peignoux M, Boyer N, Valla P, Marcellin P. Evaluation of a new assay for direct qualitative detection of serum HCV RNA. Proceedings of the AASD Annual Conference; 2001 Nov 10; Dallas, Texas. Abstract ID 236.
13. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia: a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966;40:837-56.
14. The French METAVIR Cooperative Study Group, Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
15. Musset L, Diemert MC, Taibi F, Thi Huong Du L, Cacoub P, Leger JM, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992;38:798-802.
16. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Histopathology 2000;36:69-86.
17. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologie response according to polymerase chain reaction-based assays. Hepatology 2000;32:818-23.
18. Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006;44:83-7.
19. Levine JW, Gota C, Fessier BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 2005;32:1164-7.
20. Rasul I, Shepherd FA, Kamel-Reid S, Krajden M, Pantalony D, Heathcote EJ. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999;29:543-7.
21. Luppi M, Longo G, Ferrari MG, Barozzi P, Marasca R, Morselli M, et al. Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. Ann Oncol 1998;9:495-8.
22. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125:1723-32.
23. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745-52.
24. Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005;165:101-5.
25. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005;21:653-62.
26. Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004;100:107-15.
27. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004;18:1711-6.
28. Patriarca F, Silvestri F, Fanin R, Zaja F, Sperotto A, Baccarani M. Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with α-interferon treatment. Br J Haematol 2001;112:370-2.
29. Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005;105:74-6.
30. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
31. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C Hepatology 2005;41:106-14.
32. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004;78:5867-74.
33. Lin Q, Dong C, Cooper MD. Impairment of T and B cell development by treatment with a type I interferon. J Exp Med 1998;187:79-87.
34. Shimoda K, Kamesaki K, Numata A, Aoki K, Matsuda T, Oritani K, et al. Cutting edge: Tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-α-induced suppression of B lymphocyte formation. J Immunol 2002;169:4707-11.
35. Garner JG, Hirsch MS, Schooley RT. Prevention of Epstein-Barr virus-induced B-cell outgrowth by interferon α. Infect Immun 1984;43:920-4.
36. Peters M, Walling DM, Kelly K, Davis GL, Waggoner JG, Hoofnagle JH. Immunologic effects of interferon-α in man: treatment with human recombinant interferon-α suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol 1986;137:3147-52.
37. Peters M, Ambrus JL, Zheleznyak A, Walling D, Hoofnagle JH. Effect of interferon-α on immunoglobulin synthesis by human B cells. J Immunol 1986;137:3153-7.